1. Home
  2. AUUD vs CDT Comparison

AUUD vs CDT Comparison

Compare AUUD & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Auddia Inc.

AUUD

Auddia Inc.

HOLD

Current Price

$1.20

Market Cap

2.9M

Sector

Technology

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$1.02

Market Cap

2.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUUD
CDT
Founded
2012
2019
Country
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
2.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AUUD
CDT
Price
$1.20
$1.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.4M
1.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$0.91
52 Week High
$14.60
$199.20

Technical Indicators

Market Signals
Indicator
AUUD
CDT
Relative Strength Index (RSI) 65.44 38.89
Support Level $0.67 $0.99
Resistance Level $0.81 $1.15
Average True Range (ATR) 0.11 0.11
MACD 0.02 0.01
Stochastic Oscillator 64.94 27.21

Price Performance

Historical Comparison
AUUD
CDT

About AUUD Auddia Inc.

Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: